

**Ind-Swift Laboratories Limited***Registered Office*SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Date: 30th October, 2026**Ref: ISLL:CH:2026****The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001****The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051****BSE Scrip Code: 532305****NSE Symbol: INDSWFTLAB****Sub.: Press Release in respect of Unaudited Financial Results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2026****Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release regarding the Company's financial results for the quarter ended September 30, 2026.

You are kindly requested to take the above information on record.

Thanking you,

For **IND-SWIFT LABORATORIES LTD.****PARDEEP VERMA**
Digitally signed by
PARDEEP VERMA
Date: 2026.10.30
17:39:29 +05'30'**PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY****Encl: a/a****Manufacturing Facilities:**

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com



Ind-Swift Laboratories Q2 FY27: Revenue up 50%, Op. EBITDA Surges 5.2x, PAT up 3.5x, EBITDA Margin Expands 1,279 BPS

Chandigarh, October 30th, 2026 - Ind-Swift Laboratories Limited (BSE: 532305 | NSE: INDSWFTLAB), a leading pharmaceutical formulations company with a presence across 85+ countries, announced its unaudited financial results for Q2 and H1 FY27, delivering a sharp step-up in revenue, profitability and margins.

The performance is led by the Company's earlier **transition from an API manufacturer to a Finished Dosage Formulations (FDF) manufacturer** and the **further scale-up of its operations**. The Company's **CDMO partnerships** have started to pick up and are now contributing much better to the topline, while the shift in business mix has **lifted margins**.

Operating efficiency improved alongside growth. Raw material expense fell to **45.15% of revenue** from 49.38% in Q2 FY26. Growth was driven by core operations: non-operating other income declined 35.95% to ₹7.60 crore, yet **PBT rose 3.6x to ₹40.24 crore**. Finance cost declined 33.83% to ₹1.33 crore.

Sequentially, revenue grew **26.23%** and Op. EBITDA grew 27.02% over Q1 FY27 (₹186.08 crore and ₹33.32 crore respectively), with Op. EBITDA margin improving from 17.91% to 18.02%. For H1 FY27, revenue rose **35.79% to ₹420.97 crore**, Op. EBITDA rose **4.4x to ₹75.65 crore** at a margin of 17.97%, and PAT rose 3.3x to ₹55.47 crore.

Standalone Key Financial Highlights – Q2FY27:

Particulars (₹ Crs.)	Q2 FY27	Q2 FY26	Y-o-Y Change (%)
Operating Income	234.89	156.43	↑ 50.15
Op. EBITDA	42.33	8.55	↑ 4.95x
Op. EBITDA (%)	18.02	5.46	↑ 1256.01 BPS
PAT	31.03	8.76	↑ 3.54x
PAT Margin (%)	13.21	5.60	↑ 761.18 BPS

Standalone Key Financial Highlights - H1 FY27:

Particulars (₹ Crs.)	H1 FY27	H1 FY26	Y-o-Y Change (%)
Operating Income	420.97	310.02	↑ 35.79
Op. EBITDA	75.65	16.98	↑ 4.45x
Op. EBITDA (%)	17.97	5.47	↑ 1253.66 BPS
PAT	55.47	16.88	↑ 3.29x
PAT Margin (%)	13.18	5.44	↑ 773.35 BPS

Management Commentary

Mr. N.R. Munjal, Chairman of Ind-Swift Laboratories, further stated, “Q2 FY27 is a strong validation of the strategic choices we made earlier. Our transition from an API manufacturer to a **Finished Dosage Formulations (FDF) manufacturer** and the scale-up of our operations on that platform is now clearly visible in the numbers. **Revenue grew 50.15% to ₹234.89 crore, operating EBITDA rose 5.1x to ₹42.33 crore and operating EBITDA margin expanded by 1,279 bps to 18.02%,** while PAT rose 3.5x to ₹31.03 crore, with PAT margin at 13.21%.

The shift to FDF has improved our business mix and **lifted margins**, and the scale-up of operations is delivering operating leverage. **Raw material expense fell** to 45.15% of revenue from 49.38% a year ago, a 423 bps. Growth has come from core operations, with PBT rising 3.6x to ₹40.24 crore even as non-operating other income declined.

With a **net-debt-free balance sheet**, a focused FDF platform and a stronger operating base, we remain committed to scaling operations further and sustaining profitable growth.”

About Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited is a global pharmaceutical company focused on finished dosage formulations, serving regulated and emerging markets through a diversified model spanning international exports, domestic branded formulations, and contract development & manufacturing partnerships.

Company operates manufacturing facilities with multiple international regulatory accreditations and is supported by a dedicated formulation R&D infrastructure, enabling product development, filings, and commercialization across key therapeutic segments and geographies.

Post its strategic restructuring and API & CRAMS divestment, Ind-Swift operates as a net-debt-free, pure-play formulations platform with a strong, capital-efficient balance

sheet. Backed by a robust dossier pipeline, established partnerships, and broad international presence, the Company is focused on expanding exports, strengthening CDMO visibility, and delivering sustainable growth with improving margins.

Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

For further Info Please contact

Pardeep Verma VP-Corporate Affairs and Company Secretary +91-9814131627 investor@indswiftlabs.Com	Investor Relations Advisors Confideleap Partners info@confideleap.com +(91) 85911 45959 www.confideleap.com
--	--